Catalyst
Slingshot members are tracking this event:
Vitae Pharmaceuticals(VTAE) expects to initiate a phase 1 clinical trial for VTP-38543 in Atopic Dermatitus in the second half of 2015
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VTAE |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 10, 2015
Occurred Source:
http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-newsArticle&ID=2121612
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Vtp-38543, Atopic Dermatitis, Phase 1
